EA201290316A1 - Соединения-ингибиторы фермента лактатдегидрогеназы (ldh) и фармацевтические композиции, содержащие эти соединения - Google Patents
Соединения-ингибиторы фермента лактатдегидрогеназы (ldh) и фармацевтические композиции, содержащие эти соединенияInfo
- Publication number
- EA201290316A1 EA201290316A1 EA201290316A EA201290316A EA201290316A1 EA 201290316 A1 EA201290316 A1 EA 201290316A1 EA 201290316 A EA201290316 A EA 201290316A EA 201290316 A EA201290316 A EA 201290316A EA 201290316 A1 EA201290316 A1 EA 201290316A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ldh
- lactate dehydrogenase
- enzyme inhibitors
- compounds
- involved
- Prior art date
Links
- 102000003855 L-lactate dehydrogenase Human genes 0.000 title abstract 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 title abstract 4
- 239000002532 enzyme inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 230000003071 parasitic effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000140A ITPI20090140A1 (it) | 2009-11-09 | 2009-11-09 | Composto inibitore dell'enzima lattato deidrogenasi (ldh) e composizione farmaceutica che comprende tale composto |
| PCT/EP2010/006740 WO2011054525A1 (en) | 2009-11-09 | 2010-11-05 | Compounds inhibitors of enzyme lactate dehydrogenase (ldh) and pharmaceutical compositions containing these compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201290316A1 true EA201290316A1 (ru) | 2012-10-30 |
Family
ID=42244578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201290316A EA201290316A1 (ru) | 2009-11-09 | 2010-11-05 | Соединения-ингибиторы фермента лактатдегидрогеназы (ldh) и фармацевтические композиции, содержащие эти соединения |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120309794A1 (enExample) |
| EP (1) | EP2499114A1 (enExample) |
| JP (1) | JP2013510106A (enExample) |
| CN (1) | CN102639497A (enExample) |
| AU (1) | AU2010314367A1 (enExample) |
| BR (1) | BR112012010868A2 (enExample) |
| CA (1) | CA2780136A1 (enExample) |
| EA (1) | EA201290316A1 (enExample) |
| IT (1) | ITPI20090140A1 (enExample) |
| WO (1) | WO2011054525A1 (enExample) |
| ZA (1) | ZA201203993B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITPI20110143A1 (it) * | 2011-12-20 | 2013-06-21 | Univ Pisa | Agenti terapeutici in grado di ridurre la produzione cellulare di acido lattico e composizioni farmaceutiche che comprendono tali composti |
| WO2014115764A1 (ja) * | 2013-01-25 | 2014-07-31 | 国立大学法人岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する医薬品 |
| US9750761B2 (en) | 2014-05-21 | 2017-09-05 | University Of Rochester | LDH inhibitors as treatment for fibrosis and fibrotic-related disorders |
| FR3030516B1 (fr) * | 2014-12-19 | 2019-12-27 | Galderma Research & Development | Derives sulfonamides bicycles en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
| JP6681072B2 (ja) * | 2015-02-09 | 2020-04-15 | 国立大学法人 岡山大学 | 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤 |
| CA3029489A1 (en) * | 2016-06-29 | 2018-01-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | 1h-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof |
| EP4306108A1 (en) * | 2022-07-11 | 2024-01-17 | Theodossis Theodossiou | 5-aminolevulinic acid, or an ester thereof for use in treatment of cancer based on the inhibition of lactate dehydrogenase |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1923481A1 (de) * | 1969-05-08 | 1970-11-12 | Hoechst Ag | Verfahren zur Herstellung von Amiden und Estern der 1-Hydroxy-benzimidazol-2-carbonsaeure |
| DE2060199A1 (de) * | 1970-12-08 | 1972-07-06 | Bayer Ag | 1-Hydroxy-2-carbonamido-benzimidazol-3-oxide sowie deren Alkalisalze |
| GB2065098A (en) * | 1979-12-07 | 1981-06-24 | Erba Farmitalia | N-substituted Thiazolyl Derivatives of 7-amino- cephalosporanic Acid |
| US4950602A (en) * | 1987-02-20 | 1990-08-21 | Cornell Research Foundation, Inc. | Inhibition of lactate production by pyruvate adducts |
| US4762870A (en) * | 1987-04-13 | 1988-08-09 | The Firestone Tire & Rubber Company | Rubber compositions modified with hydroxy-benz-imidazole oxides |
| JPH0331257A (ja) * | 1989-06-28 | 1991-02-12 | Kissei Pharmaceut Co Ltd | インドール誘導体の製造方法 |
| JPH0525140A (ja) * | 1991-07-22 | 1993-02-02 | Sankyo Co Ltd | ベンズイミダゾール誘導体 |
| US6169107B1 (en) * | 1993-04-28 | 2001-01-02 | Sumitomo Pharmaceutical Co., Ltd. | Indoloylguanidine derivatives |
| DE69533714T2 (de) | 1994-12-20 | 2005-03-24 | Unilever N.V. | Lactat-dehydrogenase Inhibitoren in kosmetischen Mitteln |
| JP2935102B2 (ja) * | 1996-07-04 | 1999-08-16 | 大塚化学株式会社 | インドール−２−カルボン酸エステル誘導体及び該誘導体を有効成分とする農園芸用殺菌剤 |
| WO1998036774A1 (en) | 1996-12-18 | 1998-08-27 | The Johns Hopkins University School Of Medicine | Method of treating a lactate dehydrogenase-a (ldh-a)-associated disorder |
| CA2562763A1 (en) * | 2004-04-23 | 2006-07-20 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| WO2006017494A2 (en) | 2004-08-02 | 2006-02-16 | Elizabeth Mazzio | Inhibition of anaerobic glucose metabolism |
| JP2009020453A (ja) * | 2007-07-13 | 2009-01-29 | Fujifilm Corp | 感光性組成物、硬化性組成物、カラーフィルタ用硬化性組成物、カラーフィルタ及びその製造方法、並びに、平版印刷版原版 |
| US8278436B2 (en) | 2008-07-30 | 2012-10-02 | Wisconsin Alumni Research Foundation | Glycosylated warfarin analogs and uses thereof |
-
2009
- 2009-11-09 IT IT000140A patent/ITPI20090140A1/it unknown
-
2010
- 2010-11-05 WO PCT/EP2010/006740 patent/WO2011054525A1/en not_active Ceased
- 2010-11-05 JP JP2012537324A patent/JP2013510106A/ja active Pending
- 2010-11-05 EP EP10785332A patent/EP2499114A1/en not_active Withdrawn
- 2010-11-05 BR BR112012010868A patent/BR112012010868A2/pt not_active IP Right Cessation
- 2010-11-05 US US13/508,473 patent/US20120309794A1/en not_active Abandoned
- 2010-11-05 CN CN2010800516087A patent/CN102639497A/zh active Pending
- 2010-11-05 CA CA2780136A patent/CA2780136A1/en not_active Abandoned
- 2010-11-05 AU AU2010314367A patent/AU2010314367A1/en not_active Abandoned
- 2010-11-05 EA EA201290316A patent/EA201290316A1/ru unknown
-
2012
- 2012-05-31 ZA ZA2012/03993A patent/ZA201203993B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011054525A1 (en) | 2011-05-12 |
| CA2780136A1 (en) | 2011-05-12 |
| AU2010314367A1 (en) | 2012-05-31 |
| BR112012010868A2 (pt) | 2017-02-21 |
| ITPI20090140A1 (it) | 2011-05-10 |
| CN102639497A (zh) | 2012-08-15 |
| ZA201203993B (en) | 2014-11-26 |
| EP2499114A1 (en) | 2012-09-19 |
| JP2013510106A (ja) | 2013-03-21 |
| US20120309794A1 (en) | 2012-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201290316A1 (ru) | Соединения-ингибиторы фермента лактатдегидрогеназы (ldh) и фармацевтические композиции, содержащие эти соединения | |
| EA201491786A1 (ru) | ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1 | |
| EA201391290A1 (ru) | Гетероциклические модуляторы синтеза липидов | |
| MX389666B (es) | Induccion de celulas pluripotentes. | |
| EA201100125A1 (ru) | Производные пирролопиридинилпиримидин-2-иламина | |
| UA114087C2 (xx) | Похідні піридину | |
| MX366318B (es) | Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1. | |
| UA111075C2 (uk) | Триазолопіридинові сполуки як інгібітори кінази рім | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| EA200801784A1 (ru) | Ингибиторы е1 активирующих ферментов | |
| EA201291300A1 (ru) | Производные нафт-2-илуксусной кислоты для лечения спида | |
| MY159575A (en) | Dihydroorotate dehydrogenase inhibitors | |
| EA201290980A1 (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
| EA201590554A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
| EA201291357A1 (ru) | Способы лечения с применением ингибиторов tlr7 и/или tlr9 | |
| EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| EA201501088A1 (ru) | Гетероарильные соединения, применяемые в качестве ингибиторов e1 активирующих ферментов | |
| BR112013029640A2 (pt) | derivados de piridina e pirazina | |
| WO2012104007A3 (de) | 7-azaindolderivate | |
| CA3253390A1 (en) | Alpha-amylase variants and polynucleotides encoding same | |
| EA201300442A1 (ru) | ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2 | |
| EA201290822A1 (ru) | Триазолоны в качестве ингибиторов синтазы жирных кислот | |
| TN2015000084A1 (fr) | Pyridinones bicycliques nouvelles | |
| CL2013000455A1 (es) | Compuestos derivados oxadiazol, inhibidores de la produccion de leucotrienos; composicion farmaceutica que lo comprende; y su uso en el tratamiento de enfermedades cardiovasculares, inflamatorias, alergicas, pulmonares y fibroticas y cancer. |